White-LogoEaston Pharmaceuticals, Inc designs, produces, and sells premium health care products. Most of them use the proprietary transdermal gel formulation that the Canadian company has developed. In 2013, Easton Pharma also announced that it has begun breaking into the medical marijuana sector.

The company was founded in 1997 and originally operated as LAM Pharmaceutical Corp. It became Easton Pharmaceuticals, Inc in 2010.

With a market cap pegged at USD 1.26 M, Easton Pharmaceuticals currently trades in the OTC markets as EAPH.

Products of the company are targeted towards various health issues. Most are applied topically but have transdermal effects due to Easton’s unique proprietary delivery system. There is the arthritis- and body-pain reliever Kenestrin Gel, the anti-wrinkle cream Skin Renou HA, the female sexual enhancement gel Viorra, and the motion sickness reliever gel Nauseasol.

In addition, Easton Pharmaceuticals is working on two major products in its pipeline. These are the early-stage cancer drug called XILIVE and the transdermal treatment for Female Sexual Arousal Disorder (FSAD) called Femlife.

For its entry into the marijuana industry, Easton Pharmaceuticals revealed its intention to establish medical marijuana clinics in Canada and the US. It has also started to discuss investment proposals, such as the one with a Michigan-based medical marijuana dispensary.

The company’s biggest move so far on this front is its investment in AMFIL Technologies. AMFIL is the manufacturer of a plant-growing system called the mPact-GROzone Antimicrobial System, whose technologies reduce pathogens and pests inside cannabis grow facilities.

Easton Pharmaceuticals, Inc is led by CEO and President Carla Pepe, CFO John Adams, COO Kent A Deuters, Treasurer Dr. Peter J. Rothbart, and Chief Marketing and Technology Officer Dr. Lilla Albert. Alongside them is Dr. Daniel Bagi as the Senior Executive Physician Consultant.


Yahoo! Finance: EAPH News

Latest Financial News for EAPH

Oppenheimer & Co. Inc. Announces Bob McCabe Joins Palm Beach Gardens Office As Branch Manager And Senior Director Of Investments

Oppenheimer & Co. Inc. ("Oppenheimer"), a leading wealth manager, investment bank, and a subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Bob McCabe has joined the firm as Branch Manager and Senior Director of Investments for its Palm Beach Gardens office.

Is Now The Time To Put Oppenheimer Holdings (NYSE:OPY) On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Cub Cadet helps Canadians prepare for the toughest months of the winter season with the ultimate snow blower guide

From A to Z, everything Canadians need to know about snow blowersKITCHENER, ON, Dec. 21, 2020 /CNW/ - Outdoor power equipment manufacturer, Cub Cadet, is empowering Canadians by giving them the right information to conquer Canada's toughest winter months.

Is OPY A Good Stock To Buy Now?

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Oppenheimer Holdings Inc. Declares Special Dividend

NEW YORK, Dec. 9, 2020 /CNW/ - Oppenheimer Holdings Inc.